Monitoring the efficiency of inteiferon-a therapy in chronic myelogenous Leukemia (CML) patients by competitive polymerase chain reaction

Leukemia

Volumn 11, Issue SUPPL. 3, 1997, Pages 541-544

  Hochhaus, Andreas ^a,b   Lin, Feng ^b   Reiter, Andreas ^a   Skladny, Heyko ^a   Hehlmann, Rudiger ^a   Goldman, John M ^b   Cross, Nicholas C P ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOGENETICS; DRUG EFFICACY; DRUG MONITORING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030861268     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820-825, 1994
2. Hehlmann R, Heimpel H, Hasford J and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in clironic myelogenous leukemia (CML). Blood 84:4064-4077, 1994
3. Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomised, multicentre trial of interferon-anl for clironic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 345:1392-1397,1995